References
- Skinnider B F, Mak T W. The role of cytokines in classical Hodgkin lymphoma. Blood 2002; 99: 4283–4297
- Yung L, Linch D. Hodgkin's lymphoma. Lancet 2003; 36: 943–951
- Rautert R, Schinkoethe T, Franklin J, Weihrauch M, Boell B, Pogge E, et al. Elevated pretreatment Interleukin-10 serum level is an IPS-independent risk factor for early treatment failure in advanced stage Hodgkin Lymphoma. Leuk Lymphoma 2008; 49: 2091–2098
- Sarris A H, Kliche K O, Pethambaram P, Preti A, Tucker S, Jackow C, et al. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol 1999; 10: 433–440
- Bohlen H, Kessler M, Sextro M, Diehl V, Tesch H. Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease. Ann Hematol 2000; 79: 110–113
- Herling M, Rassidakis G Z, Medeiros L J, Vassilakopoulos T P, Kliche K O, Nadali G, et al. Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome. Clin Cancer Res 2003; 9: 2114–2120
- Hohaus S, Giachelia M, Di Febo A, Martini M, Massini G, Vannata B, et al. Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma. Ann Oncol 2007; 18: 1376–1381